文献速递膀胱癌与上尿路尿路上皮癌

非肌层浸润性膀胱癌卡介苗治疗失败后的未被满足需求:国际膀胱癌组的系统评价与成本效果分析

Unmet Need in Non-muscle-invasive Bladder Cancer Failing Bacillus Calmette-Guérin Therapy: A Systematic Review and Cost-effectiveness Analyses from the International Bladder Cancer Group.
PubMed 文献 · Eur Urol Oncol · 2024-11-15

本系统评价纳入1998至2024年发表的57项研究、68个研究臂、2589例患者,评估卡介苗治疗失败后非肌层浸润性膀胱癌的保膀胱策略疗效与成本。3个月总缓解率约52.4%,12个月总缓解率78%,进展率13%;部分新药在10万美元意愿支付阈值下具成本效果。

要点

  • 卡介苗失败后保膀胱策略3个月总缓解率约52.4%,12个月总缓解率78%。
  • 12个月时伴发或单纯原位癌的完全缓解率为27.8%,乳头状病变的无复发生存率为25.4%。
  • 在10万美元/QALY阈值下,nadofaragene firadenovec具成本效果,帕博利珠单抗为优势策略。

核心结论

  • 卡介苗治疗失败的非肌层浸润性膀胱癌患者中,挽救性保膀胱治疗3个月缓解率约50%,但长期数据异质性大。
  • 近期开发的药物显示出有前景的肿瘤控制活性,部分策略可能具成本效果并改善生活质量。
  • 作者认为本综述结果凸显需要新的、更有效的治疗策略。

研究设计与样本

  • 国际膀胱癌组开展的系统评价与成本效果分析,系统检索在线数据库纳入前瞻性研究。
  • 纳入1998至2024年发表的57项研究、68个独特研究臂、共2589例患者。
  • 因研究间异质性显著未行荟萃分析,以探索性方式行敏感性分析。
  • 采用决策分析马尔可夫模型,以2年时间跨度比较美国食品药品监督管理局批准的新疗法。

主要发现

  • 全部研究中3个月总缓解率为52.4%(95%CI 45.4-59.2),伴发或单纯原位癌的完全缓解率为52.8%(95%CI 42.9-62.6),乳头状病变的无复发生存率为26.4%(95%CI 13.3-45.6)。
  • 12个月总缓解率为78%(95%CI 52.9-91.8),完全缓解率为27.8%(95%CI 21.3-35.4),无复发生存率为25.4%(95%CI 18.2-34.2)。
  • 进展率估计为13%(95%CI 9-18.2),接受根治性膀胱切除术的患者平均比例为24.7(范围0-85.7)。
  • 报告的毒性分级总体为轻度,发生剂量限制性毒性的参与者中位比例为3.4%(范围0-33.3%)。
  • 在10万美元意愿支付阈值下,与根治性膀胱切除术相比,nadofaragene firadenovec具成本效果,增量成本效果比为每质量调整生命年10014美元;nogapendekin alfa inbakicept的成本效果低于nadofaragene firadenovec,增量成本效果比为每质量调整生命年44602美元;帕博利珠单抗为优势策略,成本更低且更有效。

临床怎么用

  • 作者指出,卡介苗治疗失败的非肌层浸润性膀胱癌患者中,挽救性保膀胱治疗3个月缓解率约50%,但长期数据异质性大。
  • 作者指出,近期开发的药物显示出有前景的肿瘤控制活性。
  • 作者指出,在泌尿路上皮癌快速演变的背景下,部分治疗策略可能具成本效果并改善患者生活质量。
  • 作者认为本综述结果凸显需要新的、更有效的治疗策略。

局限性

  • 研究间存在显著异质性,未进行荟萃分析。
  • 长期数据异质性大。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Non-muscle-invasive bladder cancer (NMIBC) poses a significant clinical challenge, particularly when failing bacillus Calmette-Guérin (BCG) therapy, necessitating alternative treatments. Despite radical cystectomy being the recommended treatment, many patients are unfit or unwilling to undergo this invasive procedure, highlighting the need for effective bladder-sparing therapies. This review aims to summarize and report the evidence on the efficacy and to estimate the costs of bladder-preserving strategies used in NMIBC recurrence after failure of intravesical BCG therapy. METHODS: We systematically searched online databases for prospective studies investigating intravesical therapy, systemic therapy, or combination of both in patients treated previously with BCG. Owing to significant heterogeneity across the studies, a meta-analysis was inappropriate. A sensitivity analysis was performed in an exploratory manner. We used a decision-analytic Markov model to compare novel U.S. Food and Drug Administration-approved treatments with a 2-yr time horizon. KEY FINDINGS AND LIMITATIONS: A total of 57 studies published between 1998 and 2024, with 68 unique study arms and consisting of 2589 patients, were identified. The 3-mo overall response rate (ORR) across all studies, complete response rate (CRR) in concomitant carcinoma in situ (CIS) or CIS only disease, and recurrence-free rate (RFR) in papillary disease were estimated to be 52.4% (95% confidence interval [CI]: 45.4-59.2), 52.8% (95% CI: 42.9-62.6), and 26.4% (95% CI: 13.3-45.6), respectively. The 12-mo ORR, CRR, and RFR were estimated to be 78% (95% CI: 52.9-91.8), 27.8% (95% CI: 21.3-35.4), and 25.4% (95% CI: 18.2-34.2), respectively. The progression rate was estimated to be 13% (95% CI: 9-18.2). The mean proportion of patients treated with radical cystectomy was estimated to be 24.7 (range 0-85.7). The reported toxicity grades were overall mild, with a median of 3.4% (range 0-33.3%) participants experiencing a dose limiting toxicity. Compared with using radical cystectomy to treat patients failing BCG therapy, at a willingness-to-pay threshold of 100 000 USD, nadofaragene firadenovec was cost effective, with an incremental cost-effectiveness ratio (ICER) of 10 014 USD per quality-adjusted life year (QALY), while nogapendekin alfa inbakicept was less cost effective than nadofaragene firadenovec (ICER of 44 602 USD per QALY). Pembrolizumab, which dominated, was both less costly and more effective than the other strategies. CONCLUSIONS AND CLINICAL IMPLICATIONS: Salvage bladder-sparing therapies show a response rate of around 50% at 3 mo in patients with NMIBC failing BCG. However, long-term data are heterogeneous. Nevertheless, recently developed agents show promising tumor control activity. In the rapidly evolving landscape of urothelial cancer, some of these treatment strategies might be cost effective and improve patients' quality of life. The findings of our review highlight the need for novel, more effective therapeutic strategies. PATIENT SUMMARY: In this study, we reviewed the evidence on the efficacy of bladder-preserving strategies used in patients with bladder cancer recurrence after failing bacillus Calmette-Guérin (BCG) therapy. We found that these strategies show a response rate of around 50% at 3 mo. However, long-term data are heterogeneous. Nevertheless, recently developed agents show promising tumor control activity. In the rapidly evolving landscape of urothelial cancer, some of these treatment strategies might be cost effective and improve patients' quality of life.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. D'Andrea D, Mostafid H, Gontero P, et al. Unmet Need in Non-muscle-invasive Bladder Cancer Failing Bacillus Calmette-Guérin Therapy: A Systematic Review and Cost-effectiveness Analyses from the International Bladder Cancer Group. Eur Urol Oncol. 2024. PMID: 39550339. doi:10.1016/j.euo.2024.10.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。